Controlled release preparation containing cilostazoland process for the preparation thereof

A controlled-release preparation, the technology of cilostazol, which is applied in the field of controlled-release preparations of cilostazol, can solve the problems of large daily dose, inconvenience for patients to take comfortably, and complicated preparation methods
CN101631533AInactive Publication Date: 2010-01-20AMOREPACIFIC CORP +1
5 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
AMOREPACIFIC CORP
Publication Date
2010-01-20
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

A controlled release preparation which comprises particles containing cilostazol or its pharmaceutically acceptable salt dispersed in a solubilizing agent and an erodible material encasing said particles which is capable of forming a hydrogel, can maintain a constant level of cilostazol in the blood through its slow release during its prolonged residence time in the stomach and intestines, thereby minimizing adverse effects caused by rapid release of the drug or solubilizing agent.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to controlled release formulations of cilostazol and methods of preparing said formulations. Background technique

[0002] Cilostazol is a typical intracellular cAMP PDE (cyclic AMP phosphodiesterase) inhibitor, and it has been known that it inhibits platelet aggregation and dilates arteries by inhibiting PDE activity. It plays an important role in anti-inflammatory and anti-ulcer effects, lowering blood pressure, prevention and treatment of asthma and cerebral infarction, and improvement of cerebral circulation.

[0003] Cilostazol has poor water solubility (1 μg / ml or less), and it has been demonstrated that orally administered cilostazol is absorbed primarily in the upper gastrointestinal (GI) tract and its absorption occurs as it moves to the lower GI tract reduce. Because the conventional controlled-release dosage form of cilostazol has a limitation on the absorption time at the desired absorption site, the current ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More